Subanalysis of a pilot study (NCT01085318) assessed correlations between serum ferritin and imaging assessments in relapsing-remitting multiple sclerosis patients (n = 23) receiving 44 μg interferon beta-1a subcutaneously three times weekly. At baseline, 12, and 24 weeks, mean ferritin was 75, 127 (p b 0.001 vs baseline), and 101 (p = 0.020 vs baseline) ng/mL. No relationship between ferritin and susceptibilityweighted imaging (SWI)-filtered phase of subcortical deep gray matter was found. Increasing ferritin correlated with decreasing lesion numbers on both fluid attenuated inversion recovery and SWI phase at 12 weeks (r = − 0.62; p = 0.003; n = 21), and with decreasing gadolinium-enhancing lesion volume at 24 weeks (r = −0.71; p = 0.050; n = 8).
Introduction
Ferritin is the principal intracellular iron storage protein, acting as a buffer both to ensure that iron is available when needed and to prevent iron overload. Each of these roles is vital: iron is essential for a number of key metabolic processes, including oxidative phosphorylation and DNA synthesis; it is also integral to the formation of myelin (Da Costa et al., 2011) . However, excessive iron produces damaging reactive oxygen species through the Fenton reaction. Increased serum ferritin is usually associated with inflammation, infections, and malignancies, where it is thought to play an adaptive role by reducing the availability of iron to malignant cells. However, increases have also been correlated with disease activity in autoimmune diseases such as systemic lupus erythematosus (Zandman-Goddard and Shoenfeld, 2008) .
Hyperferritinemia has also been reported in patients with multiple sclerosis (MS); in particular, serum ferritin levels have been found to be abnormally increased in patients with progressive MS (Da Costa et al., 2011; Sena et al., 2008) . However, previous investigations have found patients with stable or relapsing-remitting MS (RRMS) to show no significant ferritin elevation versus healthy controls (Da Costa et al., 2011; Sena et al., 2008) . Up-regulation of ferritin expression may be a protective response against oxidative damage from free iron (LeVine and Chakrabarty, 2004; Sena et al., 2008) , and apoferritin has been shown to reduce disease activity in an animal model (LeVine et al., 2002) . Previous research has shown that interferon beta-1a administered subcutaneously three times weekly (IFN β-1a SC tiw) increases serum ferritin level in patients with RRMS in follow-up up to 12 months after beginning treatment, although no correlation with clinical outcomes was seen in the 43 patients studied and magnetic resonance imaging (MRI) imaging was not performed (Sena et al., 2008) .
Susceptibility-weighted imaging (SWI)-filtered phase, an indirect measure indicative of iron deposition, is particularly useful for obtaining images within subcortical deep gray matter (SDGM) tissue (Haacke et al., 2009a; Hagemeier et al., 2013b ). An SWI approach provides more sensitive detection of tissue changes indicative of iron than may be obtained with T2 hypointensity or relaxometry measurements (Haacke et al., 2004 (Haacke et al., , 2009b Zivadinov et al., 2012) . Changes in SWI-filtered phase can be used to provide additional information to complement more traditional MRI measurements, such as T1 and gadolinium-enhancing (Gd+) lesions.
Perhaps due to the recency of phase imaging, the complex relationship between the immune system, ferritin, and brain iron in vivo is poorly understood. To our knowledge, no studies have directly investigated the relationship between changes in ferritin and changes in brain iron. Since ferritin is potentially protective but also upregulated in pathology, it is not even clear a priori whether such relationships (if any) would be positive or negative. Therefore, this substudy was conducted to assess the possible relationship of abnormal (elevated) ferritin levels to SWI and conventional MRI endpoints in patients with RRMS receiving IFN β-1a SC tiw, with the null hypothesis of no relationship between serum ferritin levels and brain iron or MRI endpoints.
Material and methods
Data were obtained from a 24-week, non-randomized, open-label, two-arm pilot study (ClinicalTrials.gov ID: NCT01085318) of patients with RRMS receiving IFN β-1a SC tiw (n = 23) and healthy controls (n = 15) . The trial was conducted in accordance with the International Conference on Harmonization guidelines for Good Clinical Practice and applicable local regulations, as well as the Declaration of Helsinki. Patients gave written informed consent before participation and the protocol was approved by the University at Buffalo Health Sciences Institutional Review Board. Screening occurred within 2 weeks before a patient entered the study.
Patients were eligible for inclusion if they were 18-65 years old, with a diagnosis of RRMS according to the McDonald 2010 criteria (Polman et al., 2011) and disease duration b20 years, and were treatment-naïve or using any of the US Food and Drug Administration-approved disease-modifying drugs (except natalizumab, mitoxantrone, or IFN β-1a SC tiw). Patients were excluded if they had had a relapse within 30 days prior to screening or had received any of the following treatments: IFN β-1a SC tiw, intravenous immunoglobulin, or plasmapheresis within 3 months prior to screening; immunosuppressant agents (eg, mitoxantrone) or any other concomitant immunomodulatory therapies (eg, natalizumab) within 30 days prior to screening; or steroid treatment within 30 days prior to MRI. Other key exclusion criteria were: alanine aminotransferase N 2.5 × upper limit of normal (ULN), alkaline phosphatase N 2.5 × ULN, total bilirubin N 1.5 × ULN, total white blood cell count b 3.0 × 10 9 /L, platelet count b 75 × 10 9 /L, hemoglobin b 100 g/L, complete transverse myelitis, simultaneousonset bilateral optic neuritis, thyroid dysfunction, moderate-to-severe renal impairment, history of seizures not adequately controlled by treatment, and any serious or acute cardiac disease. Baseline assessments included physical and neurological exams, MRI scans, and laboratory tests. Blood was drawn for standard laboratory assessments (including iron) and special chemistries (including ferritin) at screening, 12 weeks, and 24 weeks; samples were sent to a central laboratory (Quest Diagnostics, Pittsburgh, PA, USA). Neuroimaging assessments were performed at baseline, Week 12, and at the Week 24/Exit Visit. MRI analyses were rater-blinded. Neurological examinations (which were not blinded) were conducted at screening and the Week 24/Exit Visit. Patients received a safety evaluation telephone call at Week 28 (4 weeks after study exit). Patients received IFN β-1a SC tiw for 24 weeks titrated over 4 weeks to a final dose of 44 μg.
Data collection
All MRI scans were carried out on a 3 Tesla (3 T) GE Signa Excite HD 12.0 (General Electric, Milwaukee, WI, USA) using a multi-channel head and neck coil. SWI was acquired using a three-dimensional flowcompensated gradient echo sequence with 64 slices, 2-mm slice thickness, field of view (FOV) = 25.6 cm × 19.2 cm, and an in-plane resolution of 0.5 mm × 1 mm (flip angle = 12°; TE/TR = 22/40 ms; acquisition time = 8:46 min:s, bandwidth = 13.89 kHz) . Conventional two-dimensional scans (proton density [PD]/T2, fluid attenuated inversion recovery [FLAIR] , and T1 SE pre-and post-contrast) were acquired with consistent voxel size (48 slices of 3-mm slice thickness, with FOV = 25.6 cm, matrix = 256 × 256, and phase FOV = 0.75). Patients received a single dose (0.1 mmol/kg) of Gd contrast. Moreover, a three-dimensional high-resolution T1-weighted image (WI) fast spoiled gradient echo sequence with a magnetization-prepared inversion recovery pulse was acquired (TE/TI/TR = 2.8/900/5.9 ms, flip angle = 10°) using 184 1-mm slices, resulting in isotropic resolution. All scans were prescribed parallel to the subcallosal line in an axial-oblique orientation with a single average.
Segmentation of SDGM structures for SWI analysis was done using FMRIB's Integrated Registration and Segmentation Tool (FIRST) on the three-dimensional T1-WI (Patenaude et al., 2011) . Additional structures (red nucleus, pulvinar nucleus, and substantia nigra) not identifiable by this method were manually delineated on the most representative SWI-filtered phase slice using JIM5 (Xinapse Systems Ltd., Northamptonshire, UK), as reported previously . Resulting segmentations were subsequently aligned to SWI phase images using a combination of FSL's linear image registration tool (FLIRT) and nonlinear image registration tool (FNIRT). An overview of the analysis method and reproducibility results used in the present study is discussed elsewhere . Fig. 1 shows SWI-filtered phase of the SDGM, with representative segmented regions overlaid.
Phase white matter (WM) lesions were classified using a manual region-of-interest approach previously shown to be reproducible (Hagemeier et al., , 2014 . Image analyses were carried out by a single operator who was blinded to clinical status. WM lesions were identified separately on T2/PD/FLAIR, T1-WI, and SWI-filtered phase maps without a priori knowledge of where the WM lesions were located with respect to the other modalities. Only round/oval WM lesions ≥3 mm in diameter were included in the study. In addition, a subset of WM lesions was visible on both SWI-filtered phase and T2/PD/ FLAIR, and a subset was visible on both SWI-filtered phase and T1-WI; these were identified a posteriori as overlapping when one or more voxels overlapped after unblinding was performed.
Images and WM lesion maps for each patient were co-registered with FMRIB's FLIRT using 6-degrees-of-freedom (rigid-body) (Jenkinson and Smith, 2001 ). Images were re-sampled using tri-linear interpolation and WM lesion maps were re-sampled with nearestneighbor interpolation using the registration matrix from their source images. A semi-automated edge detection contouring/thresholding technique was used to identify WM lesions (Zivadinov et al., 2001 .
Post-processing of the SDGM was performed to identify voxels likely to contain abnormally high amounts of iron based on their phase values.
Reference phase values for each SDGM structure were determined previously using a large sample of healthy controls . Only the voxels of SDGM structures with phase values lower than two standard deviations (SDs) below the reference group were retained, yielding structure-specific maps of voxels with abnormally low phase. Subsequently, as a measure of the level of phase decrease, the mean value of sub-threshold voxels was calculated to yield the mean phase of low phase voxels (MP-LPV). Mean phase and MP-LPV values were calculated in radians, with lower mean phase and MP-LPV values suggesting increased iron content.
Statistical methods
Sample size was based on clinical rather than statistical considerations. Twenty-five patients with RRMS were planned for inclusion in the intent-to-treat population . Changes in serum ferritin and iron levels from baseline to Week 12 and Week 24 for patients with RRMS were analyzed using paired t-tests. The possible relationship of change in ferritin levels with iron levels and with MRI endpoints was assessed in patients with RRMS using Spearman's correlation coefficient.
Results
Demographic and baseline characteristics of patients with RRMS are shown in Table 1 .
Changes in ferritin and iron levels
Of the 23 enrolled patients, ferritin levels were missing for one patient at 12 weeks and for one other patient at 24 weeks. Mean (SD) ferritin at baseline was 74.7 (75.30) ng/mL; this increased to 127.2 (109.18) ng/mL at 12 weeks (p b 0.001 vs baseline) and decreased to 101.2 (99.57) ng/mL at 24 weeks (p = 0.020 vs baseline; p = 0.034 vs 12 weeks). Fig. 2 shows changes in ferritin levels over the course of the study. Ferritin level at 12 weeks was higher than at baseline for all but one patient (out of 22). Ferritin levels for 15/21 patients decreased from 12 to 24 weeks but were still above baseline levels at Week 24 for 15/22 patients. Ferritin levels were elevated above the ULN range (232 ng/mL for women and 345 ng/mL for men) for only one woman (at Week 12 only) and one man (at Weeks 12 and 24). 
Ferritin and MRI endpoints
No relationship between changes in serum ferritin and SWI-filtered phase of the SDGM was found. There was an inverse correlation (r = − 0.62; p = 0.003; n = 21) between change in ferritin level and the number of overlapping SWI phase and FLAIR lesions after 12 weeks of therapy (i.e., as ferritin level increased, the number of overlapping SWI phase and FLAIR lesions decreased; Fig. 4A ). There was no correlation between these two measures after 24 weeks (Fig. 4B) .
There was a borderline statistically significant positive correlation (r = 0.44; p = 0.047; n = 21) between ferritin level and absolute change in T1 lesion volume after 24 weeks (ie, increase in ferritin level correlated with an increase in T1 lesion volume; Fig. 5 ). There was also a borderline significant negative correlation (r = − 0.71; p = 0.050) between ferritin and percentage change in Gd + lesion volume after 24 weeks among the eight patients with Gd+ lesions at baseline (Fig. 6) . No other significant correlations were seen between changes in serum ferritin level and lesion number or volume. Almost all patients with RRMS (22/23) had ≥1 treatment-emergent adverse event, as previously reported . As expected, injection-site reactions and influenza-like illness were the most commonly occurring events.
Discussion
In this substudy of a 24-week, non-randomized, single-center trial, patients with RRMS experienced increases in serum ferritin level after initiation of treatment with IFN β-1a SC tiw. However, these increases did not appear to be associated with increased iron deposition in the SDGM or lesion formation, as assessed by SWI-filtered phase. Previous research has indicated that the effects of IFN β-1a SC tiw include increases in serum ferritin and decreases in early lesion formation (Bastianello et al., 2011; Li et al., 1999; Sena et al., 2008) . This is consistent with the observations from this analysis, in which ferritin increase was correlated with reductions in lesions simultaneously visible on FLAIR and SWI-phase, and with reductions in Gd + lesion volume.
In this substudy, changes in serum ferritin were not accompanied by changes in serum iron. Past research has found a lack of serum iron elevation in patients with MS, even among patients with progressive disease who had elevated serum levels of ferritin (Abo-Krysha and Rashed, 2008; Sfagos et al., 2005) . Furthermore, since serum iron is subject to active transport via carrier molecules rather than directly crossing the blood-brain barrier (Moos et al., 2007) , the relationship between serum iron or ferritin levels and brain iron is complex. For example, in elderly healthy volunteers, a relationship was shown between serum iron and deep gray matter iron, but there was no corresponding relationship with serum ferritin (House et al., 2010) . However, in mice fed a short-term iron-overload diet, serum iron and liver iron were significantly increased, but there was no change in brain iron level (Johnstone and Milward, 2010) . In this study, we had a unique opportunity to combine blood assays and MRI analysis to study both serum changes and iron-sensitive MRI phase data. SWIfiltered phase is influenced by local magnetic field changes caused by paramagnetic substances such as ferritin, and thus has been proposed as a method of indirectly measuring increases in iron content in vivo (Haacke et al., 2004; Hagemeier et al., 2013a) . In this study, decreases in MP-LPV (mean phase values of only those voxels with phase values more than two SDs from the mean value observed among the reference group) (Hagemeier et al., 2013a; Zivadinov et al., 2012) were used as a measure of iron content increase in brain structures. Iron would be the most likely cause of such changes in mean phase measures, although other factors including the diamagnetic properties of myelin and regional atrophy could also potentially influence phase shifts (Bagnato et al., 2011; Langkammer et al., 2010; Yao et al., 2012; Schweser et al., 2011 Schweser et al., , 2013 . After 24 weeks of IFN β-1a SC tiw treatment, the significant changes in ferritin were not accompanied by any significant change in MP-LPV of the SDGM in this study, and there was no correlation observed between changes in MP-LPV in the SDGM and serum ferritin. There are a number of possible explanations for this lack of correlation. First, the blood-brain barrier may insulate the brain from changes in the serum. Although this has not been directly investigated in MS, cerebrospinal fluid and serum ferritin assessments have yielded dramatically different results in other diseases such as restless leg syndrome (Earley et al., 2000) . Second, it is important to note that although MRI phase-based techniques are highly sensitive to iron, they are not able to reliably distinguish among the different forms of iron (e.g., between free iron, transferrin, ferritin, and hemosiderin). Future studies with further advances in MRI techniques may be able to investigate this. Finally, it is important to note that this was a relatively small subanalysis of a pilot study, and subtle changes below our statistical threshold cannot be ruled out.
In MS lesions, oligodendrocyte destruction and demyelination can liberate iron bound to ferritin and permit it to be transformed into reactive species that can amplify oxidative damage and cellular injury (Lassmann, 2011) . The precise pathophysiological significance of the iron accumulation seen in some, but not all, MS lesions remains uncertain (Bian et al., 2013; Mehta et al., 2013) . It may be indicative of debris from breakdown of myelin or oligodendrocytes, accumulation in microglia/macrophages, or leakage from compromised blood vessels, or it may have a causal role in brain pathology (Haacke et al., 2009a; Mehta et al., 2013; Hametner et al., 2013) . Phase lesions may indicate the presence of iron, but they are possibly even more affected by changes in myelin (Bian et al., 2013; Chen et al., 2014; Wen et al., 2014; Yao et al., 2012) . The WM lesion changes seen in this study could be related to the dual effect of IFN β-1a SC tiw on both iron and myelin content (Bian et al., 2013; Eissa et al., 2009; Haacke et al., 2009a; Hagemeier et al., 2014; Mehta et al., 2013; Yablonskiy et al., 2012; Yao et al., 2012) . It is worthwhile to note that ferritin receptors are abundant in the white matter and that their distribution is reduced in and around MS lesions (Hulet et al., 1999) .
From a clinical perspective, the implication of this study is that therapy-related changes in serum ferritin do not appear to have a substantial impact on brain iron homeostasis in the short term. The precise role of iron in multiple sclerosis is still poorly understood, since iron can play a negative role in the formation of reactive oxygen species, but is also essential for oligodendrocyte function and myelination. Therefore, such a lack of interference is potentially comforting in the absence of a precise understanding of ideal brain iron levels.
The short duration and small sample size of this analysis are limitations of this study. No RRMS group receiving placebo was included. However, the results of this study can be used to guide further exploration of effects of therapy on ferritin levels in patients with RRMS and the possible contributions of ferritin and iron to phase lesion development.
Conclusions
IFN β-1a SC tiw therapy was associated with short-term increases in serum ferritin levels and reductions in lesions simultaneously visible on FLAIR and SWI phase. This association and the correlation of reduced Gd+ lesions with ferritin increase are consistent with previous research that found IFN β-1a SC tiw to increase serum ferritin and decrease early lesion formation, while an explanation for the positive correlation seen between ferritin and T1 lesion volume requires further investigation. The increases in serum ferritin levels seen were not associated with significant increases in serum iron or with concurrent iron deposition in the SDGM, as indicated by SWI. These data suggest that increased serum ferritin after initiation of IFN β-1a SC tiw does not contribute to brain iron accumulation or lesion formation. In fact, the increase in ferritin induced by IFN β-1a SC tiw was associated with a reduction in iron-containing lesions by overlapping SWI and FLAIR, although significant correlation was only seen over the first 12 weeks of treatment.
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